ImmunoForge, Co. Ltd.

MetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

Large South Korean pharma firms have reported mixed second-quarter earnings amid the ongoing medical care disruption in the country stemming from the prolonged standoff between the government and medi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . BioDelivery Gains US Rights